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Poxviruses encode soluble cytokine receptors to interfere with host immune functions. Cells infected with vaccinia virus
(V V) strains USSR, Lister, and Evans express soluble and cell surface tumor necrosis factor receptors (vTNFRs). We have
characterized vTNFR activity in V V USSR and identified an open reading frame that encodes both soluble and cell surface
activity, hereafter referred to as V V cytokine response modifier E (V V CrmE). Expression and characterization from
recombinant V V and baculovirus showed V V CrmE to be an 18-kDa protein that bound human, mouse, and rat TNF-a, but not
human LTa. V V CrmE inhibited the cytotoxic and apoptotic activities of human, but not mouse or rat, TNF in vitro.
Nonetheless, in a murine intranasal model, USSR recombinants lacking CrmE were attenuated, demonstrating a role in vivo.
Furthermore, expression of V V or cowpox virus vTNFRs from V V strain WR (which itself does not express a vTNFR) was
shown to enhance virulence in the murine model. © 2002 Elsevier ScienceKey Words: vaccinia virus; cowpox virus; tumor necrosis factor; virulence; cell surface; apoptosis; necrosis; lymphotoxin a.INTRODUCTION
Poxviruses are large DNA viruses that encode many
proteins that interfere with host immune functions, in-
cluding several that function as soluble cytokine recep-
tors or binding proteins. Poxvirus proteins that bind tu-
mor necrosis factor (TNF), interleukin 1b (IL-1b), IL-18,
interferon-g (IFN-g), IFN-a/b, and CC chemokines have
been described; for reviews see Alcamı´ and Koszinowski
(2000) and Smith (2000).
The family of TNF-like molecules comprises an in-
creasing number of secreted and membrane-bound pro-
teins, including TNFa and lymphotoxin a (LTa), reviewed
by Locksley et al. (2001). Soluble TNF and LTa function
as trimers, binding to two distinct receptors, TNFR1 (p55)
and TNFR2 (p75), to induce receptor oligomerization and
subsequent activation of intracellular signaling cas-
cades. Members of the TNFR family exhibit a character-
istic extracellular region consisting of a repeating cys-
teine-rich domain (CRD) that mediates ligand binding;
however, the intracellular domains involved in signal
transduction are more diverse. TNFR1 and TNFR2 are
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285expressed on virtually all cells of the body, with the
exception of red blood cells, and binding of TNFs to
receptors can induce a variety of responses including
cellular activation, differentiation, or death.
TNF is a pleotropic cytokine associated with many
cellular functions, including inflammation and antiviral
defense. TNFs and TNFRs mediate antiviral activity in a
number of ways, including selective killing of virus-in-
fected cells, inhibition of virus replication, and the induc-
tion of an antiviral state in uninfected cells (Mestan et al.,
1986; Wong and Goeddel, 1986; Wong et al., 1988). TNFs
are induced in response to a range of viral infections and
often act synergistically with IFN-g to mediate antiviral
responses (Wong et al., 1988; Lucin et al., 1994). Further-
more, TNF is a proinflammatory cytokine involved in the
recruitment of immune cells to sites of infection, thereby
aiding clearance of virus. In vivo, a recombinant vaccinia
virus (rVV) expressing TNFa was highly attenuated in a
mouse model of infection (Sambhi et al., 1991).
The physiological significance of TNF in poxvirus in-
fections is underscored by the observation that these
viruses encode proteins which interfere with intracellular
components downstream of TNF–TNFR binding or which
are secreted to bind and sequester TNF. Serine protease
inhibitors (serpins) encoded by cowpox, rabbitpox, vari-
ola, and vaccinia viruses inhibit intracellular caspases,
thereby mediating a number of different functions includ-
ing the blockade of TNF-mediated apoptotic cell death
(Dobbelstein and Shenk, 1996; Kettle et al., 1997). Genes
encoding proteins with sequence similarity to the N-
terminal ligand-binding CRDs of cellular TNFRs have
also been identified in several poxviruses. The first pox-
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broma virus (SFV) where expression of the SFV T2 open
reading frame (ORF) produced a soluble glycoprotein
that bound human TNF and LT (Smith et al., 1990). A
similar protein was identified in myxoma virus, and de-
letion of the vTNFR gene (M-T2) attenuated the virus in a
rabbit model of infection (Upton et al., 1991). Interestingly,
multiple different vTNFRs have been detected in some
orthopoxviruses. Cowpox virus (CPV) strain Brighton Red
encodes three different vTNFRs, termed cytokine re-
sponse modifier B (CrmB; 48 kDa) (Hu et al., 1994), CrmC
(25 kDa) (Smith et al., 1996), and CrmD (46 kDa) (Loparev
et al., 1998), that vary with respect to ligand specificity
(CrmB and CrmD bind human TNF and LTa, and CrmC
binds human TNF but not LTa) and time of expression
(CrmB is expressed early, and CrmC and CrmD are
expressed late). All three vTNFRs contain an N-terminal
domain that shares amino acid similarity with the four
CRDs of host TNFRs; however, CrmB and CrmD encode
a unique ;160-amino-acid C-terminal domain of un-
known function. Sequence analysis of CPV GRI-90 iden-
tified a fourth ORF (K3R) predicted to encode a protein of
167 amino acids with sequence similarity to members of
the TNFR superfamily (Shchelkunov et al., 1998) and the
related gene in CPV strain elephantpox virus (EP) was
shown to encode a soluble vTNFR, designated CrmE
(Saraiva and Alcamı´, 2001). A CrmB-like protein is the
only functional vTNFR predicted from known variola and
camelpox virus sequences (Aguado et al., 1992; Mas-
sung et al., 1994; Shchelkunov et al., 2000; Saraiva and
Alcamı´, 2001), while an intact CrmD is predicted in the
Moscow strain of ectromelia virus (Loparev et al., 1998).
VV strains Western Reserve (WR) and Copenhagen
encode two vTNFR genes, A53R and C22L/B28R (present
within the inverted terminal repeat and therefore diploid),
that correspond to cowpox CrmC and CrmB, respectively.
These VV vTNFR genes are truncated due to frameshift
or nonsense mutations and were predicted to be inactive
(Goebel et al., 1990; Howard et al., 1991; Upton et al.,
1991). Although most V V strains do not produce vTNFRs,
VV strains Lister, USSR, and Evans encode soluble
vTNFR activity (Alcamı´ et al., 1999). In VV strain Lister,
the A53R gene encodes an active soluble vTNFR, while
gene B28R is truncated by mutations. Interestingly, vTN-
FRs are also expressed at the surface of cells infected
with VV strains USSR, Lister, and Evans but not by CPV
or camelpox virus, and the gene(s) responsible for this
activity is unknown.
Here we have characterized soluble and cell surface
vTNFR activity encoded by VV USSR. We found that the
USSR A53R gene encoded soluble vTNFR activity and
identified an ORF in V V USSR that encoded a vTNFR
similar to the CrmE of CPV EP. VV CrmE was character-
ized further following expression from baculovirus and
recombinant VV WR and found to mediate soluble and
membrane-bound TNF-binding activity in both systems.
Finally, USSR deletion mutants lacking VV CrmE, but notCrmC, were attenuated in a murine intranasal model,
demonstrating a role for this vTNFR in vivo.
RESULTS
Analysis of A53R and B28R regions in VV strain
USSR
In VV Lister, gene A53R encodes a soluble vTNFR but
gene B28R is truncated by mutations that introduce stop
codons or frameshifts (Alcamı´ et al., 1999). The sequence
of genes A53R and B28R was determined in VV USSR
because this virus is more virulent in mice than VV Lister
(A. Khanna, A. Alcamı´, and G. L. Smith, unpublished
results) and would be more appropriate for experiments
to determine the role of vTNFRs in virus virulence. The
A53R and B28R genes were cloned from VV USSR as
described under Materials and Methods. The A53R ORF
of USSR encoded a predicted polypeptide of 186 amino
acids with an N-terminal hydrophobic sequence and two
potential N-linked glycosylation sites. VV USSR A53R
has 98% amino acid identity to VV Lister A53R and
showed sequence similarity to members of the TNFR
superfamily. The VV USSR B28R gene was found not to
encode an intact vTNFR, but only short ORFs that, when
assembled together by introduction of frameshifts, pro-
duced a complete vTNFR. The USSR B28R DNA se-
quence shared 98% nucleotide identity with the Lister
B28R gene (Alcamı´ et al., 1999) and all nonsense and
frameshift mutations were conserved.
Deletion of A53R gene in VV strain USSR
The A53R and B28R gene sequences in VV USSR
suggested that only A53R encodes a functional vTNFR.
To study the function of the A53R-encoded vTNFR, ap-
proximately 88% of this gene was deleted from VV USSR
by transient dominant selection (vDA53R). A revertant
virus was also constructed by reinserting the A53R ORF
into the deletion virus (vA53R-rev). Analysis of the ge-
nomes of vDA53R, wild-type (vWTA53R), and vA53R-rev
viruses by PCR confirmed that most of the A53R gene
was deleted from vDA53R and that the genes flanking
the A53R gene were of the expected size. Thus, the
genomic structures of the viruses around the A53R locus
were as predicted. Furthermore, the plaques formed on
BS-C-1 cells by vWTA53R, vDA53R, and vA53R-rev vi-
ruses were the same size, and the yield of intracellular
virus produced at 24 h postinfection (p.i.) at 1 PFU/cell in
BS-C-1 cells was indistinguishable for each virus (data
not shown), indicating that the A53R gene is nonessen-
tial for replication in vitro.
Thymidine kinase-negative (TK2)143B cells were in-
fected with rVVs and at 24 h p.i. the secreted and cell
surface vTNFR activity was determined in binding assays
with 125I-labeled human TNF. Despite deletion of A53R,
vDA53R still expressed soluble and membrane-bound
vTNFR to levels comparable to those of vWTA53R and
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of an additional vTNFR gene(s) in VV USSR and sug-
gested that this gene(s) encodes the majority of both
soluble and cell surface TNF-binding activity in VV
USSR. No vTNFR activity (membrane or soluble) was
found when cells were infected with vDA53R in the pres-
ence of cytosine arabinoside (AraC), an inhibitor of DNA
synthesis and therefore of intermediate and late viral
gene expression. AraC also inhibited vTNFR expression
by vWTA53R and vA53R-rev (Fig. 1), confirming that both
A53R and the gene(s) encoding the additional vTNFR/s
were expressed late during infection.
Identification of an additional ORF in VV strains
USSR, Lister, and Evans that encodes
a soluble and cell surface vTNFR
Recently, a putative protein (called K3R) with sequence
similarity to the TNFR superfamily was identified in CPV
strain GRI-90 (Shchelkunov et al., 1998). The protein
encoded by this ORF, designated CrmE, was character-
FIG. 1. TNF-binding activity of vDA53R USSR. (A) Soluble binding
assay. Supernatants from cell cultures infected with the indicated
viruses, in the absence (2) or in the presence (1) of AraC, were
incubated with human 125I-TNF. Bound 125I-TNF was determined by
precipitation with PEG and filtration. Specific 125I-TNF binding of dupli-
cate samples (mean 6 SEM) after subtraction of background radioac-
tivity is shown. (B) Membrane-binding assay. Cells infected with the
indicated viruses, in the absence (2) or in the presence (1) of AraC,
were detached from the plate, washed in binding medium, and incu-
bated for 2 h at 4°C with human 125I-TNF. Bound 125I-TNF was deter-
mined after phthlate oil centrifugation by measuring radioactivity asso-
ciated with the cell pellet in a gamma counter.ized in CPV strain EP and found to encode a soluble18-kDa vTNFR that bound human, mouse, and rat TNF-a
(Saraiva and Alcami, 2001). Combinations of specific
oligonucleotide primers designed to GRI-90 K3R ampli-
fied the K3R counterpart from genomic DNA of VV USSR.
Cognates in other VV genomes were identified by PCR
and Southern blot hybridizations. The gene was identi-
fied and sequenced in VV strains USSR, Lister, and
Evans, but could not be detected in WR, Copenhagen,
IHD-J, IHD-W, Wyeth, Lister, Tian-Tan, Tashkent, King In-
stitute, Dairen, Patwadangar, rabbitpox, or buffalopox.
The deduced amino acid sequence of CrmE from VV
USSR, Lister, and Evans was identical and predicted an
18-kDa polypeptide with a putative 17-amino-acid N-ter-
minal signal peptide and a single potential N-linked
glycosylation site at residue 71. VV CrmE differed by a
single amino acid substitution from CPV strain GRI-90
K3R (L3 P at residue 42) and CPV strain EP CrmE (S3
P at residue 82).
The presence of a 17-amino-acid N-terminal signal
peptide in VV CrmE suggested that the protein could be
secreted. Furthermore, it was reported that EP and a rVV
WR expressing EP CrmE produced soluble but not cell
surface vTNFR activity (Saraiva and Alcamı´, 2001). To
address if the VV CrmE encoded soluble and/or cell
surface vTNFRs, approximately 85% of the ORF was
deleted from VV USSR (vDCrmE) and vDA53R
(vDA53RDCrmE) by transient dominant selection. Both
wild-type and deletion mutant viruses were produced
from the same intermediate mycophenolic acid (MPA)-
resistant parent viruses (vWTCrmE and vWTDA53R, re-
spectively), and revertant viruses were produced by re-
insertion of CrmE into the deletion viruses (vCrmE-rev
and vDA53RCrmE-rev, respectively). PCR analyses con-
firmed the genomic structures of all viruses around both
the A53R and the CrmE loci (data not shown), and no
differences in plaque phenotype or yield of intracellular
virus were noted following infection of BS-C-1 cells with
these viruses (data not shown), indicating that CrmE is
nonessential for replication of VV USSR in vitro.
Cells infected with deletion mutants lacking the CrmE
counterpart (i.e., vDCrmE and vDA53RDCrmE) displayed
low levels of either membrane or soluble vTNFR activity
(Fig. 2). Significant vTNFR activity was detected in super-
natants from cells infected with vDCrmE, consistent with
the presence of an intact A53R; soluble vTNFR activity
was reduced further in supernatants from cells infected
with vDA53RDCrmE. Together, these results indicate that
CrmE is responsible for the majority of both soluble and
cell surface vTNFR activity expressed by VV USSR. Our
results also indicate that CrmE is more abundant in
supernatants than at the cell surface; 1.5 3 106 cells
infected with vWTDA53R (expressing CrmE but not A53R)
bound approximately 8000 cpm of 125I-TNF at the cell
surface (Fig. 2B), compared to 5500 cpm bound by me-
dium from 1.5 3 105 infected cells (Fig. 2A).
Previous studies have shown that supernatants from
VV Lister- or CPV-infected cultures do not confer vTNFR
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(Alcamı´ et al., 1999). To confirm that cell surface TNFR
activity of VV USSR was not due to attachment of the
secreted receptor to the surface of virus-infected cells,
perhaps due to interaction with an additional protein
encoded by VV USSR, mock-infected or vDCrmE-in-
fected cells were preincubated with supernatants from
cultures infected with WTA53R, vDA53R, or vDCrmE
which contained soluble vTNFR activity; no enhance-
ment of cell surface vTNFR activity was noted in mock- or
vDCrmE-infected cultures (data not shown).
Expression of VV crmE from VV WR and baculovirus
USSR CrmE was expressed from VV WR (which does
FIG. 2. V V USSR CrmE encodes both soluble and cell surface vTNFR
activity. (A) Soluble vTNFR activity produced by USSR-derived recom-
binant viruses. Monolayers of TK2143B cells were mock-infected or
infected with the indicated viruses at 10 PFU/cell, and the supernatants
were harvested 24 h p.i. Specific 125I-TNF binding of duplicate samples
(mean 6 SEM) after subtraction of background with medium is shown.
(B) Membrane vTNFR activity in USSR-derived recombinant viruses.
TK2143B cells were mock-infected or infected with the indicated vi-
ruses and tested for cell surface TNF-binding activity at 24 h p.i. Bound
human 125I-TNF was determined after phthlate oil centrifugation by
measuring radioactivity associated with the cell pellet in a gamma
counter.not express vTNFR activity) and from recombinant bacu-loviruses under the control of strong promoters. A protein
of 18 kDa was detected in cell pellets and supernatants
from (i) TK2143B cells infected with a rVV expressing
USSR CrmE (vCrmEUSSR) and (ii) Sf21 (Spodoptera frug-
inperda 21) cells infected with a recombinant baculovirus
expressing USSR CrmE (AcCrmEUSSR), but was absent
from cultures infected with wild-type VV WR or AcNPV
(Fig. 3A). A similar protein was also secreted into super-
natants of cells infected with rVVs or recombinant bacu-
loviruses expressing CrmE from VV Lister and Evans
(data not shown). As reported previously (Alcamı´ et al.,
1999), cells infected with recombinant VV or baculovi-
ruses expressing A53R from VV Lister (vA53RLister and
AcA53RLister, respectively) secreted a protein of approx-
imately 20 kDa (Fig. 3A).
To determine if the V V CrmE-like protein is modified
by glycosylation, cells were infected with vCrmEUSSR
in the presence or absence of either tunicamycin (an
inhibitor of N-linked glycosylation) or monensin (which
alters protein translocation through the Golgi network,
thereby inhibiting addition of O-linked glycosylation).
While tunicamycin had no effect upon the size or the
secretion of CrmE from vCrmEUSSR-infected cells,
secretion was inhibited in the presence of monensin
(data not shown). The ability of monensin to inhibit
CrmE secretion may indicate a direct effect on the
addition of O-linked carbohydrate to the protein or
perhaps an indirect effect upon the processing of the
protein within the Golgi network. As a control, another
V V-encoded protein, A41L, had a decreased size but
was still secreted from infected cells in the presence
of either tunicamycin or monensin, indicating the pres-
ence of both N- and O-linked carbohydrate (data not
shown) (Ng et al., 2001).
Deletion of A53R from V V USSR has little effect
upon levels of soluble or cell surface vTNFR activity
(Fig. 1); however, deletion mutants lacking CrmE pro-
duce very little of either vTNFR activity (Fig. 2). There-
fore it was of interest to determine the soluble and cell
surface TNF-binding activity from cells infected with
rV Vs and baculoviruses expressing V V CrmE or A53R.
TK2143B cells infected with vCrmEUSSR produced
both secreted and cell surface vTNFRs, while
vA53RLister-infected cells produced only soluble TNF-
binding activity (Fig. 3B). Similar results were obtained
after infection of BS-C-1, RK13, or CV-1 cells (data not
shown), demonstrating that the expression of cell sur-
face vTNFR activity is not particular to TK2143B cells.
Cell surface vTNFR activity was also detected in Sf21
insect cells infected with AcCrmEUSSR (Fig. 3B), indi-
cating that CrmE need not be expressed in the context
of V V infection to mediate cell surface vTNFR activity.
Again, soluble, but not cell surface, vTNFR activity was
noted following infection with baculovirus expressing
Lister A53R (AcA53RLister).
FIG. 3. Expression of vTNFRs from V V USSR by recombinant V Vs and by recombinant baculoviruses. (A) Metabolic labeling of proteins from cultures
infected with recombinant viruses. TK2143B cells were mock-infected or infected with the indicated orthopoxviruses and pulse-labeled with [35S]cysteine and
[35S]methionine from 4 to 8 h p.i. Sf21 cells were mock-infected or infected with the indicated recombinant baculoviruses and pulse-labeled from 24 to 26 h
p.i. Proteins present in cell extracts and supernatants (SNF) were analyzed by SDS–PAGE and fluorography. The positions of USSR vTNFRs A53R and CrmE
are indicated. Molecular masses in kilodaltons are shown. (B) TNF-binding activity from cultures infected with recombinant viruses. TK2143B or Sf21 cells
were mock-infected or infected with V Vs or baculoviruses, respectively. At 24 h p.i. supernatants were harvested and 100 ml was tested for binding of
125I-labeled human TNF in a soluble binding assay. Specific 125I-TNF binding of duplicate samples (mean 6 SEM) after subtraction of background with
medium is shown. Mock-infected and infected cells were also tested for cell-surface TNF-binding activity. Bound 125I-TNF of duplicate samples (mean 6
SEM) was determined after phthlate oil centrifugation by counting radioactivity associated with the cell pellet in a gamma counter.
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The specificity of the CrmE-like vTNFR was analyzed
in binding assays with culture supernatants or cells from
vCrmE-USSR-infected cells and human 125I-TNF in the
presence of excess unlabeled human LTa or TNF from
human, mouse, and rat (Fig. 4). Addition of a 1000-fold
excess of TNF from human, mouse, or rat reduced sol-
uble vTNFR activity by 90–95% (Fig. 4A); however, there
was no effect on TNF binding by the vTNFR in the
presence of an excess of unlabeled human LTa. Similar
results were obtained with culture supernatants from
TK2143B cells infected with vDA53R or from Sf21 cells
FIG. 4. Binding specificity of V V CrmE. (A) Soluble binding assay.
Supernatants from cell cultures infected with rV Vs expressing USSR
CrmE (vCrmEUSSR, equivalent to 2 3 104 cells) were incubated with
human 125I-TNF in the presence or in the absence of the indicated fold
excess of unlabeled human TNF (hTNF), human LTa (hLTa), mouse
TNF (mTNF), or rat TNF (rTNF). Bound 125I-TNF was determined after
precipitation with PEG and filtration. The percentage of 125I-TNF binding
of duplicate samples (mean 6 SEM) refers to binding in the absence
of competitor. (B) Membrane-binding assay. Cells infected with
vCrmEUSSR were detached from the plate, washed with binding me-
dium, and incubated for 2 h at 4°C with human 125I-TNF in the absence
or in the presence of the indicated fold excess of unlabeled hTNF, LTa,
mTNF, or rTNF. Bound 125I-TNF was determined after phthlate oil cen-
trifugation. Results are expressed as the percentage binding relative to
that recorded in the absence of competitor.infected with AcCrmEUSSR (data not shown). Similarly,
the membrane-bound vTNFR activity in vCrmEUSSR-in-
fected cells was reduced by 80–90% in the presence of a
1000-fold excess of TNF from human, rat, or mouse (Fig.
4B). A 1000-fold excess of cold LTa had no effect on the
cell surface vTNFR, indicating a very low affinity for this
ligand.
Next we investigated the ability of VV vTNFRs to block
binding of human TNF to cellular receptors. Supernatants
from TK2143B cells infected with vCrmEUSSR inhibited
binding of human 125I-TNF to U937 cells more efficiently
than did supernatants from vA53RLister-infected cells (Fig.
5). This difference was also observed using supernatants
from AcCrmEUSSR and AcA53RLister-infected insect cells
or mammalian cells infected with vDA53R and vDCrmE
(data not shown).
Biological activity of the soluble VV USSR CrmE
TNF-induced cell death in L929 cells is characterized
by a necrosis-like phenotype and is dependent on the
production of mitochondrial reactive oxygen species
(Goossens et al., 1995). To examine inhibition of biolog-
ical activity of TNF by soluble VV vTNFRs, cytotoxic
assays were performed using murine L929 cell targets
exposed to human, murine, or rat TNF or to human LTa.
Supernatants from vCrmEUSSR-infected cells were a po-
tent inhibitor of the lytic activity of human TNF, but not
FIG. 5. V V vTNFRs inhibit binding of 125I-TNF to U937 cellular recep-
tors. Supernatants from Sf21 cells infected with the indicated baculo-
viruses or TK2143B cells infected with V Vs were incubated with 200 pM
human 125I-TNF for 2 h on ice, and the amount of cell-associated
125I-TNF was determined following phthlate oil centrifugation. The
amount of medium used was 25 or 50 ml and corresponded to ;4 3 104
or ;8 3 104 cells, respectively. Binding was also performed in the
presence of a 1000-fold excess of unlabeled hTNF or LTa. Data are
expressed as a percentage of counts bound to cells in the presence of
competitor relative to that without (mean 6 SEM).murine or rat TNF, against L929 cells (Fig. 6). In contrast,
ntrol in
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TNF-mediated cytolysis but had little effect on human
TNF. Neither USSR CrmE nor Lister A53R was found to
block the cytolytic activity of human LTa.
The finding that CrmE inhibits the cytotoxic activity of
human TNF only is somewhat surprising since murine
TNF and rat TNF were shown to inhibit binding of 125I-
labeled human TNF to CrmE (Fig. 4). Similar findings
were reported by Saraiva and Alcamı´ (2001) using solu-
ble CrmE from CPV EP. The ability of CrmE to inhibit the
cytotoxic activity of human TNF suggests a high affinity
for human TNF and that this is sufficient to block inter-
action with cellular receptors.
Biological activity of membrane-bound VV USSR
CrmE
In contrast to necrotic cell death, induction of apopto-
sis requires the activation of cysteine proteases of the
caspase family and is accompanied by DNA fragmenta-
tion (Martelli et al., 2001). Some poxviruses encode
caspase inhibitors to prevent apoptotic cell death medi-
ated by TNF or other inducers of apoptosis (Dobbelstein
and Shenk, 1996; Kettle et al., 1997). To investigate if
FIG. 6. Inhibition of TNF-mediated cellular cytotoxicity by V V vTNFRs.
12 h of treatment with hTNF, mTNF, rTNF, or LTa as indicated. Triplica
from TK2143B cells that had been mock-infected (E) or infected with W
Results are presented as percentage cytotoxicity relative to an OD coexpression of cell surface vTNFRs could be anothermechanism by which VV-infected cells inhibit apoptotic
cell death, TNF-mediated apoptotic cell death was as-
sessed by cell cycle analysis using propidium iodide (PI)
to stain the DNA of human Saos2 cells that had been
treated with hTNF (5 U/ml) and CHX (10 mg/ml) following
mock infection or infection with different viruses. Apo-
ptotic cells were identified by subdiploid staining of DNA
due to activation of endogenous endonuclease activity
and subsequent leakage of low-molecular-weight DNA
products. The VV WR gene B13R encodes an intracellu-
lar polypeptide that protects virus-infected cells from
TNF-mediated apoptosis (Kettle et al., 1997). As ex-
pected, cells infected with a deletion mutant lacking the
B13R gene were more sensitive to hTNF-mediated apo-
ptosis than those infected with wild-type virus or with a
revertant virus in which the B13R gene had been rein-
serted into the B13R deletion mutant (Fig. 7). Immunoblot
analysis using a rabbit antiserum raised to the WR B13R
ORF expressed as a glutathione S-transferase–fusion
protein identified a 38.5-kDa protein in WR- but not
USSR-infected BS-C-1 cells (Kettle, 1995); however, de-
spite the absence of the B13R counterpart, USSR-in-
fected cells were more resistant to hTNF-mediated apo-
violet staining was used to determine the percentage cell viability after
ions of TNFs were incubated for 1 h at 4°C with 20 ml of supernatant
A53RLister (), or vCrmEUSSR (n ), prior to their addition to L929 cells.
the absence of TNF.Crystal
te dilut
R (h), vptosis than uninfected cells (Fig. 7). Cells infected with
analys
292 READING, KHANNA, AND SMITHdeletion mutants lacking USSR CrmE (vDCrmE or
vDA53RDCrmE) were sensitive to TNF-mediated apopto-
sis while cells infected with vDA53R remained resistant,
suggesting a role for CrmE, but not A53R, in protection
against hTNF-mediated apoptosis.
To determine if the protective effect of CrmE was due
to expression of the cell surface vTNFR, cells were pre-
treated for 6 h with CHX, washed to remove any secreted
CrmE, and incubated for a further 12 h with or without
hTNF. After this time supernatants were removed and
assessed for binding of 125I-hTNF as a measure of solu-
ble CrmE activity and infected cells were processed for
PI staining. Pretreatment of USSR vDA53R-infected cells
with CHX reduced CrmE secretion by .85% (no CHX 5
7654 6 655 cpm bound, CHX treatment 5 1061 6 213
cpm bound) and addition of this CHX-treated supernatant
to vDA53RDCrmE-infected cells failed to enhance their
resistance to hTNF-mediated apoptosis (data not
shown), indicating that the levels of soluble CrmE se-
creted in the presence of CHX are not sufficient to pro-
tect cells from TNF-mediated apoptosis. Together these
findings suggest that expression of cell surface CrmE is
sufficient to inhibit TNF-mediated apoptosis of cells in-
fected with VV USSR.
The role of VV vTNFRs in virulence
To assess whether V V vTNFRs affect virus virulence,
recombinant USSR viruses with deletions in A53R, in
CrmE, or in both vTNFRs were examined in murine in-
tradermal and intranasal models. Initial studies in the
intradermal model showed that BALB/c mice infected
6
FIG. 7. Inhibition of TNF-mediated apoptosis by V V vTNFRs. Human
washed, and incubated for an additional 6 h in the presence or absenc
for an additional 12 h. Apoptosis was assessed at 24 h p.i. by cell cyclewith increasing doses of V V USSR (up to 10 PFU) failedto develop, or developed only very small lesions, when
compared to mice infected with 104 PFU of VV WR (data
not shown). Furthermore, deletion of A53R or V V CrmE
failed to affect lesion size. Viruses were then compared
in the intranasal model of infection. Mice were infected
with 104 PFU of WR or with 106 PFU of USSR-derived
recombinant viruses, and weight loss was assessed
daily (Fig. 8). Mice infected with 104 PFU of VV WR lost
weight rapidly and were sacrificed on day 7 p.i. when
.25% of their original body weight had been lost (Fig. 8).
In contrast, mice infected with a 100-fold higher dose of
VV strain USSR showed only a mild loss and a rapid
regain in weight with no visible signs of illness. Deletion
of gene A53R from VV USSR had no effect on virulence
for mice in this model (Fig. 8A); however, mice infected
with either vDCrmE (Fig. 8B) or vDA53RDCrmE (Fig. 8C)
were attenuated markedly and lost little weight when
compared to wild-type and revertant controls.
To assess further the role of VV vTNFRs in vivo, mice
were infected intranasally with rVVs expressing Lister
A53R (vA53RLister) or USSR CrmE (vCrmEUSSR). A rVV
expressing an irrelevant protein from the TK locus, the
hemagglutinin from influenza virus A/Jap/305/57
(vH2Influenza; Smith et al., 1983), was also included.
Compared to VV WR, vH2Influenza was attenuated mark-
edly in the intranasal model (Fig. 9), consistent with
previous reports that disruption of the TK gene reduces
virulence in this model (Williamson et al., 1990; Taylor et
al., 1991). However, rVVs expressing either Lister A53R
or USSR CrmE displayed enhanced virulence compared
to this TK2 control. In particular, mice infected with
cells were mock-infected or infected with the indicated V Vs for 6 h,
mg/ml CHX. At 12 h p.i., hTNF was added and the cells were incubated
is after incubation with PI as described under Materials and Methods.Saos2
e of 10vCrmEUSSR lost weight rapidly and were sacrificed 8–10
293VACCINIA VIRUS CELL SURFACE TNFRsdays p.i. (Fig. 9A). Signs of illness also increased rapidly
after day 5 p.i. in vCrmEUSSR-infected animals (Fig. 8B),
and all mice in this group showed symptoms of pneu-
monia at the time of sacrifice. Infection with vA53RLister
was accompanied by a smaller weight loss (Fig. 9A) and
a modest and transient increase in signs of illness (Fig.
9B), and infected mice recovered from the infection.
Together, these results indicate that either loss (as seen
with vDCrmE or vDA53RDCrmE viruses) or overexpres-
sion (as seen with vCrmEUSSR or vA53RLister viruses) of
VV vTNFRs can influence virus virulence in the intranasal
model.
FIG. 8. Deletion of CrmE, but not A53R, attenuates V V USSR infection
in mice. Groups of five mice were mock-infected (E) or infected with 104
PFU or WR () or 106 PFU of (A) A53R-deletion series of viruses
vWTA53R ( n ), vDA53R (h), or vA53R-rev (F); (B) CrmE-deletion series
viruses vWTCrmE (n ), vDCrmE (h), or vCrmE-rev (F); (C) vWTDA53R
(n ), vDA53RDCrmE (h), or vDA53RCrmE-rev (F). Mice were weighed
daily and results are expressed as the mean percentage weight loss of
each group 6 SEM, compared with the weight immediately prior to
infection. P-values were determined using Student’s t test and indicate
mean percentage weight changes of mice infected with D viruses that
were significantly different from those of mice infected with the corre-
sponding WT viruses; (B) P , 0.001, days 6 to 14 and (C) P , 0.02;
days 7 to 12. All mice infected with WR were sacrificed when they had
lost .25% of their original body weight. No other animals were sacri-
ficed. All animals were also monitored daily for signs of illness, scored
from 1 to 4. None of the USSR-infected mice showed any signs of
illness, while WR-infected mice were sacrificed at 8 days p.i., when all
mice scored 3.Virulence of rVVs expressing CPV vTNFRs
A number of TNF-binding proteins have been charac-
terized from strains of CPV; however, their contribution to
virulence in an animal model has not been examined. We
have examined the effect of CPV CrmB, CrmC, and CrmE
on the virulence of TK2 VV WR in mice using rVVs, which
express each of these proteins under the control of a
strong synthetic promoter. Mice infected with vCrmB,
vCrmC, or vCrmEEP lost weight rapidly and were sacri-
ficed 8 to 9 days p.i., whereas a much milder disease
was noted in mice infected with vH2Influenza (Figs. 9C
and 9D).
DISCUSSION
In this study we have characterized the soluble and
cell surface vTNFR activity encoded by VV strain USSR.
As in VV Lister (Alcamı´ et al., 1999), soluble vTNFR
activity in VV USSR was encoded by the A53R gene, with
the B28R gene being inactive due to fragmentation. Fur-
thermore, we have identified an additional vTNFR in VV
USSR, Lister, and Evans, closely related to CPV EP CrmE,
which mediates both soluble and cell surface TNF-bind-
FIG. 9. Virulence of rV Vs expressing vTNFRs from V V or CPV. Groups
of five mice were mock-infected (E) or infected (A and B) with 104 PFU
of WR () or 106 PFU of rV Vs vH2Influenza (), vA53RLister (F), or
vCrmE-USSR (n ) or (C and D) with 104 PFU or WR () or 106 PFU of
rV Vs vH2Influenza (), vCPVCrmB (h), vCPVCrmC (n ), or (l). Mice
vCrmEEP were weighed daily and results are expressed as the mean
percentage weight loss of each group 6 SEM, compared with the
weight immediately prior to infection. The mean value of signs of
illness 6 SEM in each group are shown. All mice in groups infected
with WR, vCrmE-USSR, vCPVCrmB, vCPVCrmC, or vCrmEEP were sac-
rificed when their mean percentage weight reached 225%. None of the
vH2Influenza-, vA53RLister-, or PBS-inoculated mice were sacrificed.ing activity. Although secreted and membrane-bound VV
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TNF was inhibited in in vitro cytotoxicity assays. Finally,
we have examined the role of VV vTNFRs in vivo and
report that deletion of V V CrmE, but not A53R, from VV
USSR led to a marked attenuation of the virus in the
murine intranasal model of infection.
All vTNFRs identified in poxviruses show sequence
similarity to the N-terminal ligand-binding domains of
cellular TNFRs, but lack transmembrane anchoring and
cytoplasmic signaling domains. VV CrmE has these
characteristics but unlike other vTNFRs also has mem-
brane-bound vTNFR activity. Cell surface vTNFR was not
due to soluble vTNFR binding back to the cell surface,
because supernatants from USSR-infected cells did not
confer cell surface TNF-binding activity to mock-infected
or vDCrmE-infected cells, nor is this activity dependent
upon interaction with another VV-encoded protein since
activity was expressed at the surface of insect cells
infected with recombinant baculoviruses expressing
CrmE. Perhaps CrmE is transported to the cell surface
via interactions with cellular proteins, where it is retained
for a period of time before detachment or cleavage from
the cell surface. Alternatively, the N-terminal signal se-
quence may function as an anchor, such that CrmE is
retained at the cell surface with a type II membrane
topology, leaving the CRDs exposed to bind soluble TNF.
In this conformation some CrmE might be released after
proteolysis.
In a previous report, cells infected with CPV strain EP
or with recombinant V V expressing EP CrmE were found
to express soluble, but not membrane-bound, TNF-bind-
ing activity (Saraiva and Alcamı´, 2001), which is surpris-
ing given its very close sequence similarity to the VV
CrmE protein. However, we have found that EP-infected
TK2143, BS-C-1, and RK13 cells express soluble and cell
surface vTNFRs (data not shown). Expression of both
soluble and cell surface vTNFR activity tends to be
somewhat lower when compared with VV USSR, but is
enhanced by increasing the m.o.i. to 20 PFU/cell or by
incubating virus-infected cells an additional day prior to
assay. Furthermore, TK2143B cells or insect cells in-
fected with rVV or recombinant baculovirus expressing
EP CrmE were found to express soluble and membrane-
bound vTNFR activity (data not shown). It would be of
interest to determine if CPV strain GRI-90 encodes both
soluble and cell surface vTNFR activity, given that it also
differs from VV CrmE by only a single amino acid.
The cell surface vTNFR encoded by VV strains USSR,
Lister, and Evans is interesting in that the majority of
cytokine receptors or binding proteins described in pox-
viruses to date are secreted. An exception is the B18R
protein that is secreted from WR-infected cells and can
bind to infected and uninfected cells and protect these
against the induction of an antiviral state by IFN-a/b,
thereby maintaining the cells’ susceptibility to virus in-
fections (Alcamı´ et al., 2000). In contrast, CrmE is present
at the surface of virus-infected, but not uninfected, cells,where it may act to protect these cells from TNF-medi-
ated cell killing. Virus-infected cells are killed selectively
by TNF and this activity is accelerated by IFN-g (Mestan
et al., 1986; Wong and Goeddel, 1986; Wong et al., 1988);
thus CrmE expressed at the cell surface could bind TNF,
protect the cell from TNF-mediated killing, and promote
the synthesis and release of viral progeny. Secreted
CrmE binds soluble TNF and can inhibit its interaction
with cellular receptors and may thereby hinder the proin-
flammatory and antiviral properties of this cytokine. Thus,
secreted and cell surface vTNFRs could play distinct but
complementary roles in manipulating the host response
to infection.
It is curious that most VV strains do not express
vTNFR activity, yet USSR, Lister, and Evans encode two
TNF binding proteins. Other orthopoxviruses express
multiple vTNFRs simultaneously, suggesting that they
may modulate the immune system in different ways. CPV
strain Brighton Red encodes three soluble TNFRs, CrmB,
CrmC, and CrmD (Hu et al., 1994; Smith et al., 1996;
Loparev et al., 1998), while an additional vTNFR, CrmE,
has been reported in CPV strain EP (Saraiva and Alcamı´,
2001). CPV strain GRI-90 sequence data reveal five dis-
tinct ORFs with sequence similarity to TNFRs (Shch-
elkunov et al., 1998). Counterparts of CrmB (B28R/C22L),
CrmC (A53R), and now CrmE have been identified and
characterized in VV, although only the latter two encode
functional vTNFRs. It is unlikely that VV USSR expresses
additional vTNFRs, since in numerous assays we have
shown that deletion of both A53R and CrmE removes
virtually all soluble and cell surface TNF-binding activity
(Fig. 2; and data not shown). Combinations of specific
oligonucleotide primers failed to identify a CrmD coun-
terpart in genomic DNA from any of the 15 VV strains
tested in this study (data not shown). In addition, probes
generated from PCR-derived CrmD DNA failed to hybrid-
ize to USSR, Lister, or Evans genomic DNA in Southern
blot analysis (data not shown), indicating that expression
of a CrmD counterpart is unlikely.
We have examined the in vivo role of VV vTNFRs in
murine intradermal and intranasal models, thereby ex-
amining the effect of loss of VV vTNFRs in the context of
local and systemic infections, respectively. Studies in the
intradermal model were complicated by the poor ability
of wild-type USSR to induce lesions in the ears of in-
fected mice; however, deletion of vTNFRs did not alter
lesion size significantly. USSR was slightly more virulent
in the murine intranasal model; lung virus titers were low,
there was no detectable viremia, and no virus was re-
covered from other organs such as brain and spleen
(unpublished observations). This mild infection is atten-
uated further by the loss of the CrmE vTNFR, demonstrat-
ing that vTNFRs may act as virulence factors in VV
infection. Expression of VV (CrmC and CrmE) or CPV
(CrmB, CrmC, and CrmE) vTNFRs from TK2 rVVs en-
hanced virulence in the murine intranasal model, further
demonstrating the ability of poxvirus-encoded TNF-bind-
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Other studies have examined the role of poxvirus
vTNFRs in the context of an in vivo infection. MT-2, a
vTNFR encoded by myxoma virus, contributes to viru-
lence in European rabbits (Upton et al., 1991). In addition,
CPV Brighton Red mutants lacking CrmB or CrmC have
been examined in the chicken embryo chorioallantoic
membrane model (Smith et al., 1996), and the CrmB
deletion virus was shown to have a higher LD50 than
wild-type CPV in a mouse intracranial model of infection
(Palumbo et al., 1994). In our study the use of revertant
viruses, whereby the vTNFR gene of interest (A53R or
CrmE) is reinserted into the appropriate locus of the
deletion virus, strengthens the conclusion that CrmE is a
VV-encoded virulence factor in the murine intranasal
model.
Deletion of CrmE, but not A53R, attenuated VV in the
murine intranasal model despite the ability of A53R, but
not USSR CrmE, to inhibit the cytotoxic activity of murine
TNF for L929 cells. One explanation would be that levels
of A53R vTNFR produced following infection of mice are
low compared to VV CrmE and may not be sufficient to
alter viral virulence. In initial studies we observed that
deletion of A53R had little effect upon overall expression
of soluble vTNFR activity in VV USSR (Fig. 1). In addition,
the majority of soluble TNF-binding activity was lost
following deletion of CrmE (vDCrmE), despite the pres-
ence of an intact A53R (Fig. 2). Alcamı´ et al. (1999)
reported that expression of Lister A53R from VV WR
under a strong promoter did not produce as much vTNFR
activity as that present in VV Lister supernatant although
much higher levels of A53R protein were secreted into
supernatants of cells infected with the recombinant virus
(Alcamı´ et al., 1999). Together, these findings indicate
that the majority of soluble vTNFR activity expressed in
VV strains USSR and Lister is encoded by CrmE. An
alternative explanation could be that expression of mem-
brane-bound CrmE may be particularly important in pro-
moting virus dissemination and spread by protecting
infected cells from TNF-mediated killing. Another possi-
bility is that CrmE binds and inhibits another member of
the TNF ligand superfamily that is important in the con-
text of VV infection. In this regard, EP CrmE does not
bind human TRAIL, GITR, CD40L, BAFF, TWEAK, 4-1BBL,
or RANK (Saraiva and Alcamı´, 2001).
VV strains USSR, Lister, and Evans are the only VV
strains identified that secrete a CrmC-like vTNFR or
produce soluble and cell surface vTNFRs via the produc-
tion of CrmE. These strains share other common features
including the expression of a chemokine-binding protein
(Alcamı´ et al., 1998) and a mild virulence for mice.
Genomic sequencing upstream and downstream from
the USSR CrmE gene indicated similarities with the se-
quence from CPV strain GRI-90 K3R(CrmE) flanking re-
gions (data not shown). Furthermore, oligonucleotide
primers designed to these flanking genes amplified
products from genomic DNA extracted from VV USSR,Lister, and Evans, but not strains WR or Copenhagen.
These results suggest that USSR, Lister, and Evans are
closely related strains of VV and, in this region of the
genome, are more closely related to CPV than other
strains of VV.
In summary, our data demonstrate that VV USSR pro-
duces two distinct TNF-binding proteins: a soluble
vTNFR encoded by the A53R and a CrmE-like protein that
mediates both soluble and cell surface vTNFR activity.
MATERIALS AND METHODS
Cells and viruses
The orthopoxvirus strains used in this study and the
growth conditions for African green monkey BS-C-1 and
human TK2143B and U937 cells have been described
elsewhere (Alcamı´ and Smith, 1995; Alcamı´ et al., 1998).
Saos2, a human osteosarcoma cell line, was grown in
Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum. The WR recombinant VVs ex-
pressing VV Lister A53R, CPV A53R/CrmC, and CPV
B28R/CrmB have been described previously (Alcamı´ et
al., 1999). Working stocks of rVVs were prepared by
sedimentation of cytoplasmic extracts of infected cells
through a cushion of 36% (wt/vol) sucrose by centrifuga-
tion at 24,000 g for 80 min at 4°C.
Reagents
Radioiodinated human recombinant TNF (approxi-
mately 50 mCi/mg) was from DuPont–New England Nu-
clear. Recombinant human, murine, and rat TNF and
human LTa were obtained from Peprotech, and each had
a specific activity of $2 3 107 units/mg.
Plasmid constructions
VV strain USSR genomic DNA was used for cloning
the A53R and B28R genes into pBluescript SK vector as
follows. Gene A53R was located in an ;2.0-kb EcoRV
fragment by Southern blot analysis of USSR virus DNA
and hybridization with an A53R probe amplified by PCR.
Following EcoRV digestion of the virus DNA, an ;2.0 kb
fragment was cloned into EcoRV-pBS SK, and this plas-
mid was called pAK1. Similarly, the USSR B28R gene was
located in an ;2.1 kb AvaI fragment in USSR virus DNA.
The fragment was made blunt-ended by treatment with
Klenow DNA polymerase and cloned into EcoRV-di-
gested pBS, and the plasmid was named pAK3. Virus
DNA cloned into plasmids pAK1 and pAK3 was se-
quenced using M13 forward and reverse universal prim-
ers and oligonucleotides specific for genes A53R (from
WR) and B28R (Copenhagen/WR). Sequencing reactions
were carried out using the ABI PRISM Dye Terminator
Cycle Sequencing Ready Reaction Kit and run on an ABI
373 DNA sequencer according to the manufacturer’s
instructions. Sequence data were analyzed using the
Staden (Bonfield et al., 1995) and GCG (Genetics Com-
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Plasmids were constructed for making VV USSR dele-
tion mutants lacking A53R (pDA53R) or VV CrmE (pDCrmE)
as follows. Oligonucleotides that flanked the left or right
side of the A53R gene or the CrmE gene were used to
generate PCR products that contained terminal restriction
enzyme sites. For pDA53R, 59-CCCGTCGACTGCATGCGTG-
GTAGATG-39 and 59-CATAAGCTTATATTATCATATACTA-
CAAT-39 containing 59 SalI and HindIII sites (underlined),
respectively, were used to amplify the left flank, and 59-
GGTAAGCTTTGCGACTACCT-39 and 59-CCCGGATC-
CAGCGTATATATGTAGAAATCG-39 containing 59 HindIII and
BamHI sites, respectively, were used to amplify the right
flank. For pDCrmE, 59 TAAGGAATTCGGAAAGACATTATTA-
CACG-39 and 59-ATTCGAGCTCGACACCTTGTTCA-
CATTTC-39 containing 59 EcoRI and SacI sites, respectively,
were used to amplify the left flank, and 59-TAAG-
GAGCTCTAAGACTTACTCGCATCTAC-39 and 59-ATTCG-
GATCCGCATAACGACATGCACATC-39 containing SacI and
BamHI sites, respectively, were used to amplify the right
flank. The amplified products were digested with the rele-
vant restriction enzymes and ligated into plasmid pSJH7
(Hughes et al., 1991). Plasmid pDA53R lacked 88% of the
A53R ORF (codons 1–163) and pDCrmE lacked 84% of the
CrmE ORF (codons 27–167) and both plasmids contained
the Escherichia coli guanine phosphoribosyl transferase
(Ecogpt) gene (Boyle and Coupar, 1988) under the control of
the VV p7.5K promoter (Mackett et al., 1982). Plasmid
pA53R-rev was constructed by generating a wild-type copy
of the VV USSR A53R and flanking sequences by PCR
using virus genomic DNA as template and cloning the
products between the SalI and the BamHI sites of plasmid
pSJH7. Plasmid pCrmE-rev was constructed in a similar
manner by cloning VV USSR CrmE and flanking sequences
between the EcoRI and the BamHI sites of pSJH7. The
sequence of PCR-derived inserts from all plasmids was
confirmed by sequencing.
Construction of VV USSR deletion mutants
VV USSR deletion mutants were constructed by tran-
sient dominant selection using the Ecogpt gene as a
selectable marker as described previously (Falkner and
Moss, 1990). Briefly, CV-1 cells were infected with VV
USSR and transfected with pDA53R or pDCrmE, and
recombinant viruses were selected in the presence of
mycophenolic acid (MPA). An intermediate plaque con-
taining the full-length gene and its deleted version were
resolved by plaque purification on the hypoxanthine gua-
nine phosphoribosyl transferase (hgprt)-negative HeLa
cell line D98OR in the presence of 6-thioguanine to form
deletion (D) and wild-type (WT) plaque-purified viruses
(vWTA53R and vDA53R, and vWTCrmE and vDCrmE). To
construct a deletion virus lacking both A53R and CrmE,
CV-1 cells were infected with VV vDA53R and trans-
fected with pDCrmE, and MPA-resistant viruses wereresolved into deletion (vDA53RDCrmE) or WT (vDA53RWT)
viruses. Revertant viruses (vA53R-rev, vCrmE-rev, and
vDA53RCrmE-rev) were constructed in a similar manner,
using vDA53R, vDCrmE, or vDA53RDCrmE, respectively, as
parent viruses and plasmids pA53R-rev (for vA53R-rev) and
pCrmE-rev (for vCrmE-rev and vA53RCrmE-rev). All virus
isolates were plaque-purified three times and their
genomic structures were confirmed by PCR with primers
flanking the relevant gene (A53R, CrmE, or both) and with
primers corresponding to the appropriate flanking genes,
and by Southern blot analysis using DNA extracted from
virus cores (Esposito et al., 1981) and a probe correspond-
ing to the region deleted in the A53R or CrmE genes.
Construction of recombinant baculoviruses
VV USSR CrmE was amplified by PCR using oligonucle-
otides 59-ATTGGGATCCCATTATTGACTTAACGATGACG-39
and 59-ATTGCTCGAGTTATCTTGTCATTGGTTTACATTG-39
that introduced BamHI and XhoI sites (underlined), respec-
tively. The DNA fragment was digested with these enzymes
and cloned into BamHI and XhoI-cut pBAC-1 (R&D Sys-
tems, Abingdon, U.K.) generating plasmid pAcCrmE so that
the CrmE ORF was downstream of the Autographa califor-
nica nuclear polyhedrosis virus (AcNPV) polyhedron gene
promoter. Plasmid pAcCrmE and linear AcNPV DNA
(BacPAK6, Clontech) were used to construct recombinant
baculoviruses AcCrmEUSSR by transfection into Sf21 cells
(Alcamı´ and Smith, 1995).
Construction of rVVs
VV USSR gene CrmE was amplified by PCR with virus
DNA as template and oligonucleotides 59-ATTGGGATC-
CCATTATTGACTAAACGATGACG-39 and 59-TAACCCGCG-
GCTTATCTTGTCATTGGTTTAC-39 that contained BamHI
and SacII sites (underlined), respectively. Resultant prod-
ucts were cloned into BamHI and SacII-digested pMJ601
(Davison and Moss, 1990) to create plasmid pTKCrmE and
the sequence of the insert was confirmed by DNA sequenc-
ing. The plasmid was transfected into VV WR-infected cells
and TK2 rVVs were screened for b-galactosidase expres-
sion and plaque-purified three times (Chakrabarti et al.,
1985). The presence of VV CrmE in the rVV (designated
vCrmEUSSR) was confirmed by PCR analysis. A similar
strategy, using CPV EP DNA as a template, was employed
to generate a TK2 rVV expressing the CrmE gene from EP
(vCrmEEP).
Metabolic labeling of proteins and electrophoretic
analysis
Sf21 cells or TK2143B cells were infected with recom-
binant baculoviruses or VVs, respectively, at 10 PFU/cell.
At the indicated times postinfection, cultures were
washed and labeled for 2 h with 70 mCi of Pro-mix
L-[35S]methionine and L-[35S]cysteine in vitro cell labeling
mix (.1000 Ci/mmol, Amersham) in methionine- and
cysteine-free medium in the absence of serum. Super-
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and cells were dissociated in sample buffer. Superna-
tants and cells were analyzed by SDS–PAGE in 15% gels
and by fluorography with Amplify (Amersham).
Cytolytic assays
The ability of VV vTNFRs to inhibit TNF or LTa cyto-
toxicity for L929 cells was examined using a crystal violet
staining method (Smith et al., 1996). Briefly, serial dilu-
tions of TNF or LTa were incubated at 4°C for 1 h with
supernatants from TK2143B cells that were mock-in-
fected or infected for 24 h at 10 PFU/cell with WR,
vA53RLister, or vCrmEUSSR. Samples were incubated
with 5 3 104 L929 cells/well in 96-well plates in the
presence of 1 mg/ml actinomycin D at 37°C for 12 h and
stained with 0.5% crystal violet in methanol/water (1/4).
All assays were performed in triplicate and the percent-
age cytotoxicity was calculated as (ODmedium 2 ODTNF)/
ODmedium.
Apoptosis assays
Apoptosis was assessed by cell cycle analysis using
PI staining and flow cytometry (Vermes et al., 2000).
Human Saos2 cells were grown to confluency in 6-well
plates and infected with VV at 5 PFU/cell for 6 h. Cells
were washed with DMEM and left untreated or treated
with 10 mg/ml cycloheximide (CHX). After 6 h, the cells
were washed in DMEM and treated with TNFa, CHX, or
TNF/CHX for 10 h at 37°C. The cells were detached in
PBS containing 4 mM EDTA, washed twice, and fixed in
80% methanol at 4°C for 4 h before being stained with 50
mg/ml PI and 50 mg/ml of RNase A. At least 10,000
stained cells were examined for DNA content by flow
cytometry and apoptotic cells were located in the sub-
diploid region (i.e., the cell population showing increased
DNA fragmentation). A marker was set on the subdiploid
region in uninfected and untreated cells, and this marker
was applied to all other cell populations tested. Cell
debris was excluded from analysis using forward scat-
ter/side scatter gating.
Cell surface and soluble TNF-binding assays
Supernatants from V V-infected TK2143B cells or bac-
ulovirus-infected Sf21 cells were harvested at 1 or 3 days
p.i., respectively, and prepared as described (Alcamı´ and
Smith, 1992). All binding and competition assays were
carried out in duplicate using RPMI medium containing
1% FBS and 20 mM HEPES, pH 7.5. Soluble TNF-binding
assays were performed by incubating supernatants,
equivalent to ;105 cells, with 100–250 pM human recom-
binant 125I-TNF in a final volume of 150 ml for 2 h at room
temperature. The ligand–receptor complexes were pre-
cipitated with polyethylene glycol (PEG) and the precip-
itate was collected on Whatman GF/C filters as de-
scribed (Alcamı´ and Smith, 1992). Nonspecific binding
precipitated with binding medium alone or determined inthe presence of excess unlabeled TNF was subtracted.
In the cell surface-binding assay, uninfected or infected
TK2143B cells were detached from plates by incubation
with 10 mM EDTA in phosphate-buffered saline. Cells
(1.5 3 106) were washed twice with binding medium (1%
FBS, 20 mM HEPES, RPMI medium) by centrifugation
and incubated in binding medium with 100–250 pM hu-
man recombinant 125I-TNF for 2 h at 4°C in 150 ml. Bound
125I-TNF was determined by phthalate oil centrifugation
as described (Alcamı´ and Smith, 1992).
Virulence assays in mice
For intradermal infections, groups of five female
BALB/c mice (6 weeks old) were anesthetized and either
104 or 106 PFU of VV in PBS was injected intradermally
into the left ear pinna. The diameter of lesions was
estimated daily to the nearest 0.5 mm using a microme-
ter. For intranasal infections, groups of five female
BALB/c mice (6 weeks old) were inoculated under gen-
eral anesthesia with viruses in 20 ml of PBS. Each day,
mice were weighed individually and monitored for signs
of illness, and those suffering a severe infection or hav-
ing lost 25% of their original body weight were sacrificed.
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